InSilicoTrials Technologies
Hyper-accelerate drug and medical device development. Computational models and AI allow to dramatically accelerate the development of new drugs and medical devices, reduce, refine and replace tests on animals and clinical trials, improve the safety of medical products, and significantly cut R&D costs.
InSilicoTrials has built an online platform, where Modeling & Simulation is easy to use, regulatory compliant, and cost-effective.
Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources.
We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us.
In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.
Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources.
We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us.
In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.
Mario Torchia
VP sales and marketing
Luca Emili
CEO (founder & CEO)
Isogenica
Isogenica are experts in VHHs - highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
VHHs can be assembled to create bi- and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Isogenica’s bespoke partnerships with global biopharmaceutical companies have resulted in a deep pipeline including two Clinical Phase assets and partnered pre-clinical and discovery programs.We are also seeking to out-license in-vivo validated pre-clinical stage VHH assets, including half-life extension modules.
Dr David Mead
Director Business Development
